Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 8/20 | 1.00 |
| ▸ | SHBG | P04278 | 7/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 1.00 |
| ▸ | SERPINA6 | P08185 | 6/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 5/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 5/20 | 1.00 |
| ▸ | LMNA | P02545 | 5/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | TSHR | P16473 | 3/20 | 1.00 |
| ▸ | BLM | P54132 | 2/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 2/20 | 1.00 |
| ▸ | NR3C1 | P04150 | 6/20 | 0.78 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.78 |
| ▸ | MAPT | P10636 | 3/20 | 0.78 |
| ▸ | MEN1 | O00255 | 2/20 | 0.78 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.78 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.78 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.74 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cortodoxone SCHEMBL16834876 | 1.00 | HSD17B10 (1.00) | HSD17B10SHBGSMN1; SMN2SERPINA6CYP2C19 | |
| Cortodoxone SCHEMBL13768127 | 1.00 | HSD17B10 (1.00) | HSD17B10SHBGSMN1; SMN2SERPINA6CYP2C19 | |
| Cortodoxone SCHEMBL1592553 | 1.00 | HSD17B10 (1.00) | HSD17B10SHBGSMN1; SMN2SERPINA6CYP2C19 | |
| Cortodoxone SCHEMBL1592718 | 1.00 | HSD17B10 (1.00) | HSD17B10SHBGSMN1; SMN2SERPINA6CYP2C19 | |
| Cortodoxone SCHEMBL42590 | 1.00 | HSD17B10 (1.00) | HSD17B10SHBGSMN1; SMN2SERPINA6CYP2C19 | |
| Cortodoxone SCHEMBL24900239 | 1.00 | HSD17B10 (1.00) | HSD17B10SHBGSMN1; SMN2SERPINA6CYP2C19 | |
| Cortodoxone SCHEMBL14360590 | 1.00 | HSD17B10 (1.00) | HSD17B10SHBGSMN1; SMN2SERPINA6CYP2C19 | |
| Cortodoxone SCHEMBL17906542 | 1.00 | HSD17B10 (1.00) | HSD17B10SHBGSMN1; SMN2SERPINA6CYP2C19 | |
| Cortodoxone SCHEMBL13352414 | 1.00 | HSD17B10 (1.00) | HSD17B10SHBGSMN1; SMN2SERPINA6CYP2C19 | |
| SCHEMBL9070396 | 0.91 | HSD17B10 (0.84) | HSD17B10SHBGSMN1; SMN2SERPINA6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210161968-A1 | USE OF MICRONEEDLE PATCH TO PROMOTE HAIR GROWTH | NORTH CAROLINA STATE UNIVERSITY | 2021-06-03 | — | — | US | disclosed |
| US-10646497-B2 | 17α-monoesters and 17α,21-diesters of cortexolone for use in the treatment of tumors | COSMO TECHNOLOGIES LIMITED (IE) | 2020-05-12 | — | — | US | disclosed |
| US-20190175618-A1 | 17ALPHA-MONOESTERS OF CORTEXOLONE FOR USE IN THE TREATMENT OF TUMORS | COSMO TECHNOLOGIES LTD. (IE) | 2019-06-13 | — | — | US | disclosed |
| EP-2966175-B1 | PHARMACEUTICAL COMPOSITIONS CONTAINING CORTEXOLONE-17-ALPHA-PROPIONATE | CASSIOPEA S P A (IT) | 2019-05-08 | — | — | EP | disclosed |
| US-20190091240-A1 | 17A-MONOESTERS AND 17A,21-DIESTERS OF CORTEXOLONE FOR USE IN THE TREATMENT OF TUMORS | COSMO TECHNOLOGIES LTD. (IE) | 2019-03-28 | — | — | US | disclosed |
| US-10231980-B2 | Cortexolone 17alpha-benzoate for use in the treatment of tumours | COSMO TECHNOLOGIES LTD. (IE) | 2019-03-19 | — | — | US | disclosed |
| US-10183030-B2 | 17α,21-diesters of cortexolone for use in the treatment of tumors | COSMO TECHNOLOGIES LIMITED (IE) | 2019-01-22 | — | — | US | disclosed |
| US-20170360806-A1 | CORTEXOLONE 17ALPHA-BENZOATE FOR USE IN THE TREATMENT OF TUMOURS | COSMO TECHNOLOGIES LTD. (IE) | 2017-12-21 | — | — | US | disclosed |
| US-20170304318-A1 | 17A,21-DIESTERS OF CORTEXOLONE FOR USE IN THE TREATMENT OF TUMORS | COSMO TECHNOLOGIES LTD. (IE) | 2017-10-26 | — | — | US | disclosed |
| EP-3204012-A1 | CORTEXOLONE 17ALPHA-BENZOATE FOR USE IN THE TREATMENT OF TUMOURS | Cosmo Technologies Ltd (IE) | 2017-08-16 | — | — | EP | disclosed |
| EP-2503004-B1 | Cortexolone-17alpha-propionate in crystalline form I | CASSIOPEA S P A (IT) | 2015-09-02 | — | — | EP | disclosed |
| EP-2503005-B1 | Cortexolone-17alpha-propionate in hydrate crystalline form IV | CASSIOPEA S P A (IT) | 2015-09-02 | — | — | EP | disclosed |
| EP-2173891-B1 | Enzymatic process for obtaining cortexolone-17-alpha-propionate in crystalline form III | COSMO DERMATOS SRL (IT) | 2014-02-12 | — | — | EP | disclosed |
| EP-2503004-A1 | Cortexolone-17alpha-propionate in crystalline form I | Cosmo S.p.A. (IT) | 2012-09-26 | — | — | EP | disclosed |
| EP-2503005-A2 | Cortexolone-17alpha-propionate in cristalline hydrate form IV | Cosmo S.p.A. (IT) | 2012-09-26 | — | — | EP | disclosed |
| EP-2173891-A2 | ENZYMATIC PROCESS FOR OBTAINING 17 ALPHA-MONOESTERS OF CORTEXOLONE AND/OR ITS 9,11-DEHYDRODERIVATIVES | Cosmo S.p.A. (IT) | 2010-04-14 | — | — | EP | disclosed |
| WO-2009019138-A2 | ENZYMATIC PROCESS FOR OBTAINING 17 ALPHA-MONOESTERS OF CORTEXOLONE AND/OR ITS 9,11-DEHYDRODERIVATIVES | COSMO SPA (IT) | 2009-02-12 | — | — | WO | disclosed |
| EP-0690069-B1 | Process for the preparation of 20-oxo, 17-alpha, 21 dihydroxy steroid derivatives and new intermediates thereof | HOECHST MARION ROUSSEL INC (FR) | 2000-01-26 | — | — | EP | disclosed |
| EP-0690069-A1 | Process for the preparation of 20-oxo, 17-alpha, 21 dihydroxy steroid derivatives and new intermediates thereof | ROUSSEL UCLAF (FR) | 1996-01-03 | — | — | EP | disclosed |
| US-4089852-A | Process for the preparation of 21-hydroxy-16-pregnen-20-one derivatives | SCHERING AKTIENGESELLSCHAFT (DT) | 1978-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190091240-A1 | 17A-MONOESTERS AND 17A,21-DIESTERS OF CORTEXOLONE FOR USE IN THE TREATMENT OF TUMORS | CYP17A1, CYP11B1, CYP19A1 | HSD17B10 181/4885SHBG 267/4885SMN1; SMN2 3553/4885 |
| US-20170304318-A1 | 17A,21-DIESTERS OF CORTEXOLONE FOR USE IN THE TREATMENT OF TUMORS | CYP17A1, CYP11B1, NR5A1 | HSD17B10 279/4885SHBG 357/4885SMN1; SMN2 3466/4885 |
| US-10646497-B2 | 17α-monoesters and 17α,21-diesters of cortexolone for use in the treatment of tumors | CYP17A1, CYP11B1, CYP19A1 | HSD17B10 181/4885SHBG 271/4885SMN1; SMN2 3323/4885 |
| US-20170360806-A1 | CORTEXOLONE 17ALPHA-BENZOATE FOR USE IN THE TREATMENT OF TUMOURS | CYP17A1, CYP11B1, CYP19A1 | HSD17B10 325/4885SHBG 276/4885SMN1; SMN2 3203/4885 |
| US-10231980-B2 | Cortexolone 17alpha-benzoate for use in the treatment of tumours | CYP17A1, CYP11B1, CYP19A1 | HSD17B10 325/4885SHBG 276/4885SMN1; SMN2 3203/4885 |
| US-20190175618-A1 | 17ALPHA-MONOESTERS OF CORTEXOLONE FOR USE IN THE TREATMENT OF TUMORS | CYP17A1, CYP11B1, NR5A1 | HSD17B10 260/4885SHBG 210/4885SMN1; SMN2 3653/4885 |
| US-10183030-B2 | 17α,21-diesters of cortexolone for use in the treatment of tumors | CYP17A1, NR5A1, CYP11B1 | HSD17B10 268/4885SHBG 191/4885SMN1; SMN2 3801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.